JAK2 Exon 12, 13, 14, 15 mutation analysis

Alphabetical Test listing

JAK2 Exon 12, 13, 14, 15 mutation analysis-13516

JAK2 Exon 12, 13, 14, 15 mutation analysis

The JAK2 V617F (exon 14) mutation analysis can be used in conjunction with bone marrow histology and cytogenetic analysis to assist in the diagnosis of myeloproliferative neoplasma (MPN). The JAK2 V617F mutation is found in almost all patients with polycythemia vera (PV) and in nearly one-half of those with idiopathic myelofibrosis (IMF) and with essential thrombocythemia (ET). A small percentage (~3.3%) of JAK2 mutation positive patient contain other non-V617F mutations within exons 12 to 15.

EDTA whole blood


5.0 mL
3 mL whole blood

Lavender (EDTA), Na heparin (green), yellow (ACD) topped tube or sterile via

Sodium heparin (Na hep) whole blood - Dk green Sodium heparin (Na hep)
ACD whole blood - Yellow
2.0 mL bone marrow
Minimum 1.0 mL bone marrow


  • Specimen does not meet all of the criteria for sample type, container, minimum volume, collection and storage
  • Frozen whole blood or marrow
  • Leaking tube
  • Clotted blood or marrow
  • Grossly hemolyzed or otherwise visibly degraded
  • Contamination by another specimen
  • Specimen containing foreign material
LabCorp RTP (115101): R-LC
Testing performed at Integrated Oncology and CMBP (Center for Molecular Biology and Pathology)
Mo - Sa
6 - 9 days

Reverse transcription polymerase chain reaction RT-PCR and Sanger sequencing


An interpretive report will be provided

Result 48726-4